BACKGROUND: A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancer patients receiving chemotherapy. METHODS: The study population consisted of 3760 patients with common solid tumors or malignant lymphoma who were beginning a new chemotherapy regimen at 115 practice sites throughout the United States. A regression model for neutropenic complications was developed and then validated by using a random split-sample selection process. RESULTS: No significant differences in the derivation and validation populations were observed. The risk of neutropenic complications was greatest in cycle 1 with no significant difference in predicted risk between the 2 cohorts in univariate analysis. After adjustment for cancer type and age, major independent risk factors in multivariate analysis included: prior chemotherapy, abnormal hepatic and renal function, low white blood count, chemotherapy and planned delivery ≥85%. At a predicted risk cutpoint of 10%, model test performance included: sensitivity 90%, specificity 59%, and predictive value positive and negative of 34% and 96%, respectively. Further analysis confirmed model discrimination for risk of febrile neutropenia over multiple chemotherapy cycles. CONCLUSIONS: A risk model for neutropenic complications was developed and validated in a large prospective cohort of patients who were beginning cancer chemotherapy that may guide the effective and cost-effective use of available supportive care.
BACKGROUND: A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancerpatients receiving chemotherapy. METHODS: The study population consisted of 3760 patients with common solid tumors or malignant lymphoma who were beginning a new chemotherapy regimen at 115 practice sites throughout the United States. A regression model for neutropenic complications was developed and then validated by using a random split-sample selection process. RESULTS: No significant differences in the derivation and validation populations were observed. The risk of neutropenic complications was greatest in cycle 1 with no significant difference in predicted risk between the 2 cohorts in univariate analysis. After adjustment for cancer type and age, major independent risk factors in multivariate analysis included: prior chemotherapy, abnormal hepatic and renal function, low white blood count, chemotherapy and planned delivery ≥85%. At a predicted risk cutpoint of 10%, model test performance included: sensitivity 90%, specificity 59%, and predictive value positive and negative of 34% and 96%, respectively. Further analysis confirmed model discrimination for risk of febrile neutropenia over multiple chemotherapy cycles. CONCLUSIONS: A risk model for neutropenic complications was developed and validated in a large prospective cohort of patients who were beginning cancer chemotherapy that may guide the effective and cost-effective use of available supportive care.
Authors: J Crawford; H Ozer; R Stoller; D Johnson; G Lyman; I Tabbara; M Kris; J Grous; V Picozzi; G Rausch Journal: N Engl J Med Date: 1991-07-18 Impact factor: 91.245
Authors: Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher Journal: J Clin Oncol Date: 2004-09-20 Impact factor: 44.544
Authors: Michelle Shayne; Eva Culakova; Debra Wolff; Marek S Poniewierski; David C Dale; Jeffrey Crawford; Gary H Lyman Journal: Cancer Date: 2009-11-15 Impact factor: 6.860
Authors: Gabriel A Brooks; Ankit J Kansagra; Sowmya R Rao; James I Weitzman; Erica A Linden; Joseph O Jacobson Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Jeremy Brown; Corita Grudzen; Demetrios N Kyriacou; Ziad Obermeyer; Tammie Quest; Donna Rivera; Susan Stone; Jason Wright; Nonniekaye Shelburne Journal: Ann Emerg Med Date: 2016-02-26 Impact factor: 5.721
Authors: Carlos Chiatti; Silvia Bustacchini; Gianluca Furneri; Lorenzo Mantovani; Marco Cristiani; Clementina Misuraca; Fabrizia Lattanzio Journal: Drug Saf Date: 2012-01 Impact factor: 5.606